Project Details
| Status | Finished |
|---|---|
| Effective start/end date | 3/14/13 → 8/31/19 |
Funding
- PPD Development (GS-US-321-0106)
- Gilead Sciences, Inc. (GS-US-321-0106)
Protocol # GS-US-321-0106: A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase-Like 2 (LOXL2), in Subjects with Compensated Cirrhosis Secon
- Flamm, Steven L (PD/PI)
Project: Research project